Urinary prostate protein glycosylation prof|ling as a diagnostic biomarker for prostate cancer

Prostate

Volumn 75, Issue 3, 2015, Pages 314-322

  Vermassen, Tijl ^a   Van Praet, Charles ^a   Lumen, Nicolaas ^a   Decaestecker, Karel ^a   Vanderschaeghe, Dieter ^b   Callewaert, Nico ^b   Villeirs, Geert ^a   Hoebeke, Piet ^a   Van Belle, Simon ^a   Rottey, Sylvie ^a   Delanghe, Joris ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Benign prostate hyperplasia; Diagnostic marker; Gleason score; Prostate cancer; Urinary asparagine linked glycosylation

Indexed keywords

PROSTATE PROTEIN; BIOLOGICAL MARKER; PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FUCOSYLATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROTEIN GLYCOSYLATION; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; URINARY GLYCOPROFILE MARKER; ADOLESCENT; DIFFERENTIAL DIAGNOSIS; GLYCOSYLATION; METABOLISM; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; GLYCOSYLATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEINS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84920747180     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22918     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Lin K, Lipsitz R, Miller T, Janakiraman S, Force USPST. Benefits and harms of prostate-specific antigen screening for prostate cancer: An evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 192-199.
3. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. American Urological A. Prostate specific antigen best practice statement: 2009 update. J Urol 2013; 189: S2-S11.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
5. Vermassen T, Speeckaert MM, Lumen N, Rottey S, Delanghe JR. Glycosylation of prostate specific antigen and its potential diagnostic applications. Clin Chim Acta 2012; 413: 1500-1505.
6. Lumen N, Fonteyne V, De Meerleert G, Ost P, Villeirs G, Mottrie A, De Visschere P, De Troyer B, Oosterlinck W. Population screening for prostate cancer: An overview of available studies and meta-analysis. Int J Urol 2012; 19: 100-108.
7. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70.
8. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, Investigators E. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
9. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-1329.
10. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics 2011; 8: 7.
11. Arnold JN, Saldova R, Hamid UM, Rudd PM. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 2008; 8: 3284-3293.
12. Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, Regnier FE, Gibson BW, Fisher SJ. Sweetening the pot: Adding glycosylation to the biomarker discovery equation. Clin Chem 2010; 56: 223-236.
13. Dwek MV, Brooks SA. Harnessing changes in cellular glycosylation in new cancer treatment strategies. Curr Cancer Drug Targets 2004; 4: 425-442.
14. Dwek MV, Jenks A, Leathem AJ. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin Chim Acta 2010; 411: 1935-1939.
15. Okada T, Sato Y, Kobayashi N, Sumida K, Satomura S, Matsuura S, Takasaki M, Endo T. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochim Biophys Acta 2001; 1525: 149-160.
16. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha 2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 2011; 21: 195-205.
17. Peracaula R, Barrabes S, Sarrats A, Rudd PM, de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers 2008; 25: 207-218.
18. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004; 10: 429-434.
19. Vermassen T, Van Praet C, Vanderschaeghe D, Maenhout T, Lumen N, Callewaert N, Hoebeke P, Van Belle S, Rottey S, Delanghe J. Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer. Electrophoresis 2014; 35: 1017-1024.
20. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Fütterer JJ. European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-757.
21. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A singleinstitution experience of 356 patients. Eur J Radiol 2011; 77: 340-345.
22. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
23. Orsonneau JL, Douet P, Massoubre C, Lustenberger P, Bernard S. An improved pyrogallol red-molybdate method for determining total urinary protein. Clin Chem 1989; 35 (11): 2233-2236.
24. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of prostate carcinoma and its precursor in Hungary: An autopsy study. Eur Urol 2005; 48: 739-744.
25. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Sykes J, Lockwood G, van der Kwast TH. Prevalence of prostate cancer on autopsy: Cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013; 105: 1050-1058.
26. Holmström B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: Longitudinal study. BMJ 2009; 339: b3537.
27. Ørsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 2012; 61: 865-874.
28. Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Agerelated galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 1988; 167: 1731-1736.
29. Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 1997; 14: 401-405.
30. Knezevic A, Gornik O, Polasek O, Pucic M, Redzic I, Novokmet M, Rudd PM, Wright AF, Campbell H, Rudan I, Lauc G. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology 2010; 20: 959-969.
31. Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: Biology and clinical relevance. Am J Kidney Dis 2003; 42: 658-676.
32. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006; 126: 855-867.
33. Packer NH, von der Lieth CW, Aoki-Kinoshita KF, Lebrilla CB, Paulson JC, Raman R, Rudd P, Sasisekharan R, Taniguchi N, York WS. Frontiers in glycomics: Bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 2008; 8: 8-20.
34. Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, Malczewski S, KattanMW, Jones JS. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol 2013.
35. Lawrentschuk N, Klotz L. Active surveillance for favorable-risk prostate cancer: A short review. Korean J Urol 2010; 51: 665-670.
36. Vickers AJ, Thompson IM, Klein E, Carroll PR, Scardino PT. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology 2014; 83: 592-596.